• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Roth Capital upgrades AtriCure stock

Roth Capital upgrades AtriCure stock

January 4, 2011 By MedCity News

yyyy logo

Investment bank Roth Capital Partners upgraded shares of AtriCure Inc. (NSDQ:ATRC) to “Buy” and raised its target price by nearly 30 percent.

AtriCure, a cardiac surgical device maker, will enter “a new phase” during the next two years in which its growth rate will improve, according to a new report from two Roth analysts. That’s due to several factors, including an expansion of its U.S. sales territories, further adoption of its surgical products and a continued increase in international sales.

Roth raised its target price on AtriCure’s shares to $13.50 from $10.50. In late-morning trading, AtriCure’s shares were up more than 3 percent to $10.59. Roth had previously rated AtriCure’s stock as “Neutral.”

MedCity News logo

Roth also sees growth potential in AtriCure due to several milestones the West Chester, Ohio-based company looks to accomplish. One is simply increasing sales of its AtriClip device, which is a clip used during heart surgery to exclude the left atrial appendage. The device has “the potential to become a stand-alone franchise targeting a $150 million opportunity,” the report said. It’s used to help protect atrial fibrillation patients from strokes. The AtriClip received U.S. regulatory clearance for sales last year.

A recently started clinical trial that involves a “hybrid” approach to treating persistent atrial fibrillation patients also holds promise for AtriCure, Roth said. The procedure being evaluated in the study combines AtriCure’s minimally invasive surgical ablation devices with a catheter-based ablation system from BioSense Webster. The study, called DEEP AF, has “the potential to validate a new treatment technique for an [atrial fibrillation] population that remains ostensibly underserved today,” according to the report.

Other promising signs for AtriCure — and its investors — come from two recent acquisitions of cardiac device companies. Medtronic Inc. (NYSE:MDT) acquired ATS Medical Inc. for $370 million in April, and St. Jude Medical Inc. (NYSE:STJ) bought AGA Medical for $1.3 billion in October.

“The two acquisitions in the space leave AtriCure with an implied market value substantially higher than today’s levels,” Roth said.

Could AtriCure be the next cardiac device maker to be scooped up by one of the big players? It’s likely that possibility sent investors scurrying to buy the company’s shares Tuesday morning — and the report from Roth didn’t hurt either.

Filed Under: Business/Financial News, News Well Tagged With: AtriCure Inc., Cardiac Rhythm Management

More recent news

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Apreo Health emerges from stealth with positive data for lung scaffold
  • Tivic adds new vagus nerve stim patent
  • Study backs Teleflex stapler for reducing post-op GERD rates

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy